Cost Effectiveness of Influenza Vaccination in Older Adults

  title={Cost Effectiveness of Influenza Vaccination in Older Adults},
  author={A. Newall and H. Kelly and S. Harsley and Prof. Paul A. Scuffham},
  • A. Newall, H. Kelly, +1 author Prof. Paul A. Scuffham
  • Published 2012
  • Medicine
  • PharmacoEconomics
  • AbstractSeveral recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50–64 years. We identified and reviewed all costeffectiveness studies of influenza vaccination in those aged 50–64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates… CONTINUE READING
    29 Citations

    Tables and Topics from this paper.

    Economic Evaluations of Childhood Influenza Vaccination
    • 20
    Uncertainty and variability in influenza cost‐effectiveness models
    Economic value of influenza vaccination
    • 19
    Issues in the Economic Evaluation of Influenza Vaccination by Injection of Healthy Working Adults in the US
    • 4
    Implementing an Influenza Vaccination Programme for Adults Aged ≥ 65 Years in Poland
    • 14


    Mortality benefits of influenza vaccination in elderly people: an ongoing controversy.
    • 497
    • Highly Influential
    • PDF
    Economic Evaluations of Influenza Vaccination in Healthy Working-Age Adults
    • 25
    Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
    • 125
    • Highly Influential
    Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    • K. Nichol
    • Medicine
    • Archives of internal medicine
    • 2001
    • 265
    • PDF
    The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.
    • 60
    • Highly Influential
    The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    • 69
    • Highly Influential
    Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    • 94
    Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults
    • 131
    • PDF
    The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    • 32
    • Highly Influential